Evidence for the use of probiotics and prebiotics in inflammatory bowel disease: a review of clinical trials.
Human subjects and their enteric microbiota have evolved together to reach a state of mutual tolerance. Mounting evidence from both animal models and human studies suggests that inflammatory bowel disease (IBD) represents a malfunction of this relationship. The enteric microecology therefore represents an attractive therapeutic target with few side effects. Probiotics and prebiotics have been investigated in clinical trials as treatments for IBD, with conflicting results. The evidence for the use of probiotics in the management of pouchitis is persuasive and several studies indicate their effectiveness in ulcerative colitis. Trials of probiotics and prebiotics in Crohn's disease are less convincing. However, methodologies vary widely and a range of probiotic, prebiotic and combination (synbiotic) treatments have been tested in a variety of patient groups with an assortment of end points. Conclusions about any one treatment in a specific patient group can therefore only be drawn on evidence from relatively small numbers of patients. The present article reviews the role of the intestinal microbiota in the pathogenesis of IBD and addresses the clinical evidence for the therapeutic manipulation of bowel microbiota using probiotics, prebiotics and synbiotics in IBD.
Hedin
Charlotte
C
Nutritional Sciences Division, King's College London, London SE1 9NH, UK.
Whelan
Kevin
K
Lindsay
James O
JO
D002986:Clinical Trials as Topic; D003093:Colitis, Ulcerative / Q000382:microbiology / Q000628:therapy; D003424:Crohn Disease / Q000382:microbiology / Q000628:therapy; D019317:Evidence-Based Medicine; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000382:microbiology* / Q000628:therapy*; D019449:Pouchitis / Q000382:microbiology / Q000628:therapy; D019936:Probiotics / Q000627:therapeutic use; D016896:Treatment Outcome